Unknown

Dataset Information

0

Proteomic analysis of breast cancer based on immune subtypes.


ABSTRACT:

Background

Immunotherapy is applied to breast cancer to resolve the limitations of survival gain in existing treatment modalities. With immunotherapy, a tumor can be classified into immune-inflamed, excluded and desert based on the distribution of immune cells. We assessed the clinicopathological features, each subtype's prognostic value and differentially expressed proteins between immune subtypes.

Methods

Immune subtyping and proteomic analysis were performed on 56 breast cancer cases with neoadjuvant chemotherapy. The immune subtyping was based on the level of tumor-infiltrating lymphocytes (TILs) and Klintrup criteria. If the level of TILs was ≥ 10%, it was classified as immune-inflamed type without consideration of the Klintrup criteria. In cases of 1-9% TIL, Klintrup criteria 1-3 were classified as the immune-excluded subtype and Klintrup criteria not available (NA) was classified as NA. Cases of 1% TILs and Klintrup 0 were classified as the immune-desert subtype. Mass spectrometry was used to identify differentially expressed proteins in formalin-fixed paraffin-embedded biopsy tissues.

Results

Of the 56 cases, 31 (55%) were immune-inflamed, 21 (38%) were immune-excluded, 2 (4%) were immune-desert and 2 (4%) were NA. Welch's t-test revealed two differentially expressed proteins between immune-inflamed and immune-excluded/desert subtypes. Coronin-1A was upregulated in immune-inflamed tumors (adjusted p = 0.008) and α-1-antitrypsin was upregulated in immune-excluded/desert tumors (adjusted p = 0.008). Titin was upregulated in pathologic complete response (pCR) than non-pCR among immune-inflamed tumors (adjusted p = 0.036).

Conclusions

Coronin-1A and α-1-antitrypsin were upregulated in immune-inflamed and immune-excluded/desert subtypes, respectively. Titin's elevated expression in pCR within the immune-inflamed subtype may indicate a favorable prognosis. Further studies involving large representative cohorts are necessary to validate these findings.

SUBMITTER: Jeon Y 

PROVIDER: S-EPMC10905797 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Proteomic analysis of breast cancer based on immune subtypes.

Jeon Yeonjin Y   Lee GunHee G   Jeong Hwangkyo H   Gong Gyungyub G   Kim JiSun J   Kim Kyunggon K   Jeong Jae Ho JH   Lee Hee Jin HJ  

Clinical proteomics 20240229 1


<h4>Background</h4>Immunotherapy is applied to breast cancer to resolve the limitations of survival gain in existing treatment modalities. With immunotherapy, a tumor can be classified into immune-inflamed, excluded and desert based on the distribution of immune cells. We assessed the clinicopathological features, each subtype's prognostic value and differentially expressed proteins between immune subtypes.<h4>Methods</h4>Immune subtyping and proteomic analysis were performed on 56 breast cancer  ...[more]

Similar Datasets

2024-06-16 | PXD043902 | Pride
| S-EPMC4725767 | biostudies-literature
| S-EPMC10624674 | biostudies-literature
| S-EPMC5884642 | biostudies-literature
| S-EPMC8850446 | biostudies-literature
| S-EPMC10077467 | biostudies-literature
| S-EPMC9139462 | biostudies-literature
| S-EPMC8202402 | biostudies-literature
2017-03-29 | MSV000080757 | MassIVE
| S-EPMC6145347 | biostudies-literature